Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
131. |
ECCT/24/05/03 | SIBP-MMR-02 A Phase III, Multi-Center, Randomized, Observer-Blind, Active Controlled Non-Inferiority Study to Evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.’s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children, 9- 11 Months of Age |
Principal Investigator(s) 1. Dr Walter Otieno 2. Dr. Diana Odhiambo Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. Victoria Biomedical Research Institute (Kisumu county) |
27-05-2024 |
View |
132. |
ECCT/24/05/06 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) - Kisumu (Kisumu county) |
27-05-2024 |
View |
133. |
ECCT/24/03/06 | PHOENIx MDR-TB) Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB) |
Principal Investigator(s) 1. Dr Lucy Chepkurui Koech KOECH Site(s) in Kenya 1. Kenya medical Research Institute/ Walter Reed Project (Kericho county) 2. Moi university clinic research Centre (Uasin Gishu county) |
21-05-2024 |
View |
134. |
ECCT/24/03/02 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr. Janet Nyawira Oyieko Site(s) in Kenya 1. KEMRI CCR – Butere Clinical Research Centre (Kakamega county) |
14-05-2024 |
View |
135. |
ECCT/24/03/05 | 221163 PALISADE Long-Term Follow-Up of CAB LA for Participants in HPTN 083 and HPTN 084 CAB PrEP Studies at Risk of HIV Acquisition |
Principal Investigator(s) 1. Grace Mboya Site(s) in Kenya KEMRI Kisumu Clinical Research Site |
10-05-2024 |
View |
136. |
ECCT/23/12/02 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL) |
Principal Investigator(s) 1. Dr. Maricianah Onono Site(s) in Kenya 1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 2. Walter Reed Army Institute of Research -Kericho Site (Kericho county) 3. KEMRI CCR – Butere Clinical Research Centre (Kakamega county) 4. Siaya County Referral Hospital (SCRH) (Siaya county) 5. Kenya Medical Research Institute Center for Microbiology Research (CMR) (Kisumu county) 6. KAVI - Institute of Clinical Research (KAVI - ICR) (Nairobi City county) 7. Kombewa Clinical Research Center, KEMRI, (Kisumu county) |
10-05-2024 |
View |
137. |
ECCT/24/04/08 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Wilson Muraya Site(s) in Kenya 1. KEMRI Mtwapa Clinical Research Site- Kilifi (Kilifi county) |
08-05-2024 |
View |
138. |
ECCT/24/05/01 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Videlis Nduba Site(s) in Kenya 1. KEMRI Centre for Clinical Respiratory Diseases Research (KEMRI CRDR)-Nairobi (Nairobi City county) |
08-05-2024 |
View |
139. |
ECCT/24/05/02 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Jacqueline Mirera Site(s) in Kenya 1. Clinical Research Health Network (CREA-N), Machakos Level 5 Hospital Site (Machakos county) |
08-05-2024 |
View |
140. |
ECCT/23/12/03 | CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr Benson Ochieng Singa Site(s) in Kenya 1. Migori County Referral Hospital (Migori county) |
07-05-2024 |
View |